Baranowska-Kortylewicz J - Search Results

1

Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.

Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJ, Pavlinkova G, Batra SK. Goel A, et al. Cancer Res. 2000 Dec 15;60(24):6964-71. Cancer Res. 2000. PMID: 11156397

2

Radiolabeled iododeoxyuridine: safety evaluation.

Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, Chiou RK. Harrison KA, et al. J Nucl Med. 1996 Apr;37(4 Suppl):13S-16S. J Nucl Med. 1996. PMID: 8676196

3

Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72.

Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, Tempero M, Colcher D. Blanco I, et al. J Clin Immunol. 1997 Jan;17(1):96-106. doi: 10.1023/a:1027396714623. J Clin Immunol. 1997. PMID: 9049790

4

Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49.

Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero MA. Leichner PK, et al. J Nucl Med. 1997 Apr;38(4):512-6. J Nucl Med. 1997. PMID: 9098192 Free article.

5

Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization.

Goel A, Beresford GW, Colcher D, Pavlinkova G, Booth BJ, Baranowska-Kortylewicz J, Batra SK. Goel A, et al. J Biochem. 2000 May;127(5):829-36. doi: 10.1093/oxfordjournals.jbchem.a022676. J Biochem. 2000. PMID: 10788792 Free article.

6

High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.

Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D. Tempero M, et al. Clin Cancer Res. 2000 Aug;6(8):3095-102. Clin Cancer Res. 2000. PMID: 10955789 Clinical Trial.

7

Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.

Goel A, Augustine S, Baranowska-Kortylewicz J, Colcher D, Booth BJ, Pavlinkova G, Tempero M, Batra SK. Goel A, et al. Clin Cancer Res. 2001 Jan;7(1):175-84. Clin Cancer Res. 2001. PMID: 11205906

8

99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.

Goel A, Baranowska-Kortylewicz J, Hinrichs SH, Wisecarver J, Pavlinkova G, Augustine S, Colcher D, Booth BJ, Batra SK. Goel A, et al. J Nucl Med. 2001 Oct;42(10):1519-27. J Nucl Med. 2001. PMID: 11585867 Free article.

9

Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a.

Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA, Baranowska-Kortylewicz J. Kurizaki T, et al. J Nucl Med. 2002 Jul;43(7):957-67. J Nucl Med. 2002. PMID: 12097469 Free article.

10

Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting.

Pavlinkova G, Batra SK, Colcher D, Booth BJ, Baranowska-Kortylewicz J. Pavlinkova G, et al. Peptides. 2003 Mar;24(3):353-62. doi: 10.1016/s0196-9781(03)00049-4. Peptides. 2003. PMID: 12732332

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74 results

Search Page

Filters